High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant

It remains a global health priority to develop a durable and highly efficacious malaria vaccine. The most advanced malaria vaccine candidate, RTS,S/AS01 has completed Phase III testing in a multicentre study across several African sites and demonstrates low-level (~30%) efficacy against clinical mal...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Venkatraman, N, Bowyer, G, Edwards, NJ, Griffiths, O, Powlson, J, Silman, D, Morter, R, Folegatti, PM, Minassian, AM, Poulton, ID, Collins, K, Brod, F, Angell-Manning, P, Berrie, E, Brendish, N, Glenn, G, Fries, L, Baum, J, Blagborough, AM, Roberts, R, Lawrie, AM, Lewis, DJ, Faust, SN, Gilbert, S, Ewer, KJ, Hill, AV
Định dạng:	Conference item
Được phát hành:	American Society of Tropical Medicine and Hygiene 2017

High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant

Những quyển sách tương tự